Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab.

Abstract

Rituximab is a monoclonal antibody that targets the uniquely expressed B-cell CD20 receptor. Although recently approved for treatment of follicular lymphomas, the intracellular events that occur when rituximab binds to CD20 are largely unknown. Quantitative proteomic analysis of B-cell lymphoma-derived cells exposed to rituximab was performed. Differentially expressed proteins belonged to functional groups involved in migration, adhesion, calcium-induced signaling, ubiquitination, and components of the phosphoinositol and NF-kappaB pathways. Our studies reveal the proteomic consequences of rituximab treatment and provide novel insights into the mechanism of action of the drug in susceptible B-cell lymphoproliferative disorders.

• Authors: Kathryn L Everton, David R Abbott, David K Crockett, Kojo S J Elenitoba-Johnson, Megan S Lim
• Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (J Chromatogr B Analyt Technol Biomed Life Sci) Vol. 877 Issue 13 Pg. 1335-43 (May 01 2009) ISSN: 1873-376X [Electronic] Netherlands
• PMID: 19010092 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Neoplasm Proteins
• Rituximab
• Caspase 3

Topics

• Amino Acid Sequence
• Antibodies, Monoclonal (pharmacology)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (pharmacology)
• Blotting, Western
• Caspase 3 (biosynthesis, metabolism)
• Chromatography, Liquid
• Databases, Protein
• Enzyme Induction
• Flow Cytometry
• Humans
• Lymphoma, Follicular (metabolism, pathology)
• Molecular Sequence Data
• Neoplasm Proteins (metabolism)
• Proteomics
• Rituximab
• Tandem Mass Spectrometry
• Tumor Cells, Cultured